Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Krka
(https://krka.biz) 📸 Data Snapshot: May 30, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Living A Healthy Life | Krka (https://krka.biz)
Title
Living A Healthy Life | Krka
H2 Krka around the world
H2 For Healthcare Professionals
H2 Do you want to logout?
H2 LIVING A HEALTHY LIFE
H2 News
H2 Product search
H2 Share information
H2 BECOME PART OF A DEDICATED TEAM
H2 Movie about Krka
H2 Continue browsing
H3 2.4 tonnes of donations and 65 litres of blood: numbers that tell the story of Krka’s solidarity
H3 Krka Reports First Quarter 2026 Business Results
H3 Proposed dividend for Krka shareholders 10.3% higher than last year
H3 About us
H3 Sustainability
H3 Health matters
H3 Entry points
H3 Contact us
H3 Contact
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Health matters | Krka (https://krka.biz/health-matters/)
Title
Health matters | Krka
H2 Krka around the world
H2 For Healthcare Professionals
H2 Do you want to logout?
H2 Health matters
H2 Product search
H2 Continue browsing
H3 Valuable health information
H3 CLINICALLY PROVEN
H3 QUALITY
H3 SCIENCE AND TECHNOLOGY
H3 Entry points
H3 Contact us
H3 Contact
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Employment | Krka (https://krka.biz/employment/)
Title
Employment | Krka
H2 Krka around the world
H2 For Healthcare Professionals
H2 Do you want to logout?
H2 Employment
H2 WHY WORK AT KRKA?
H2 AREAS OF WORK
H2 EMPLOYEES SHARE THEIR STORIES
H2 BECOME A PART OF OUR SUCCESS
H2 News
H2 Continue browsing
H3 2.4 tonnes of donations and 65 litres of blood: numbers that tell the story of Krka’s solidarity
H3 Krka once again tops the rankings for reputation and influence
H3 Krka receives Krka was awarded the TOP investor in learning and development Certificate for the fourth consecutive year
H3 SUSTAINABILITY
H3 ABOUT US
H3 SCIENCE AND TECHNOLOGY
H3 Entry points
H3 Contact us
H3 Contact
NAV_HEADER_HEADING_REPEATED_BODY Financial reports | Krka (https://krka.biz/investors/financial-reports/)
Title
Financial reports | Krka
H2 Krka around the world
H2 For Healthcare Professionals
H2 Do you want to logout?
H2 FINANCIAL REPORTS
H2 News
H2 Continue browsing
H3 2026
H3 2025
H3 2024
H3 2023
H3 2022
H3 2021
H3 2020
H3 2019
H3 2018
H3 2017
H3 2016
H3 2015
H3 2014
H3 2013
H3 2012
H3 2011
H3 2010
H3 2009
H3 2008
H3 2007
H3 Arhiv
H3 2006
H3 2005
H3 2004
H3 2003
H3 2002
H3 Krka Reports First Quarter 2026 Business Results
H3 Proposed dividend for Krka shareholders 10.3% higher than last year
H3 Krka Releases 2025 Unaudited Financial Statements
H3 WOULD YOU LIKE TO LEARN MORE?
H3 SHARE INFORMATION
H3 SHAREHOLDER STRUCTURE
H3 FINANCIAL CALENDAR
H3 Entry points
H3 Contact us
H3 Contact
H4 2025 ANNUAL REPORT
H4 Interim Report
H4 ANNUAL REPORT
H4 Interim Report
H4 FINANCIAL STATEMENTS
H4 ANNUAL REPORT
H4 Interim Report
H4 Financial Statements
H4 ANNUAL REPORT
H4 Interim Report
H4 Financial Statements
H4 ANNUAL REPORT
H4 Interim Report
H4 Financial Statements
H4 ANNUAL REPORT
H4 INTERIM REPORT
H4 FINANCIAL STATEMENTS
H4 ANNUAL REPORT
H4 INTERIM REPORT
H4 FINANCIAL STATEMENTS
H4 ANNUAL REPORT
H4 INTERIM REPORT
H4 FINANCIAL STATEMENTS
H4 ANNUAL REPORT
H4 INTERIM REPORT
H4 FINANCIAL STATEMENTS
H4 ANNUAL REPORT
H4 INTERIM REPORT
H4 FINANCIAL STATEMENTS
H4 ANNUAL REPORT
H4 INTERIM REPORT
H4 FINANCIAL STATEMENTS
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Financial Statements
H4 Annual Report
H4 Interim Report
H4 Annual Report
H4 Interim Report
H4 FINANCE
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://krka.biz) Living A Healthy Life | Krka
[IMG: Slideshow slide] [H2] LIVING A HEALTHY LIFE Health is a value and a responsibility we put above everything else. Krka is one of the leading generic pharmaceutical companies with 70 years of experience. Today, the high quality of our products is recognised all over the world. Our achievements have been built by generations of Krka employees through their courageous and visionary outlook. Our attitude to people, the environment and the natural heritage as well as our strategic business direction all contribute to a better quality of life. Movie about Krka Operating figures are dynamic. The latest operating figures are published in the latest Annual Report. [H2] News [IMG: 2.4 tonnes of donations and 65 litres of blood: numbers that tell the story of Krka’s solidarity] 22. 5. 2026 [H3] 2.4 tonnes of donations and 65 litres of blood: numbers that tell the story of Krka’s solidarity Krka volunteers demonstrated yet again that mutual support, collaboration and willingness to help constitute the core values that bring Krka employees together. For the thirteenth consecutive year, nearly 1,000 volunteers helped spread a culture of care and cooperation through a wide range of activities across Slovenia and 24 other countries. [IMG: Krka Reports First Quarter 2026 Business Results] 14. 5. 2026 [H3] Krka Reports First Quarter 2026 Business Results In the first quarter of 2026, the Krka Group generated revenue of €565.8 million and operating profit of €151.6 million, confirming long-term stable sales growth and sustained operating profitability. EBITDA margin stood at 31%. [IMG: Proposed dividend for Krka shareholders 10.3% higher than last year] 2. 4. 2026 [H3] Proposed dividend for Krka shareholders 10.3% higher than last year The Krka Supervisory Board and Management Board drew up a proposal that Krka pays its shareholders a dividend of €9.10 gross per share, which is an increase of 10.3% on last year’s dividend. More [H2] Product search In our commitment to healthy living we offer a broad range of high-quality prescription pharmaceuticals, non-prescription products and animal health products. Prescription pharmaceuticals Non-prescription products Animal health products [H2] Share information KRKG-. -. — –:–Data delayed 15 minutes.Data source: LJSE. STABLE DIVIDEND GROWTH STRATEGY [H3] We pursue a long-term strategy of stable dividend growth and allocate at least 50% of net profit of majority shareholders for dividends each year. From 2014 to 2024, the gross dividend per share increased on average by 13.6%. More 2021-10-12,308.0455,111 2021-10-13,184.5625,111.5 2021-10-14,391.449,112.5 2021-10-15,367.7925,112 2021-10-18,500.861,112 2021-10-19,272.9405,111.5 2021-10-20,212.74,112.5 2021-10-21,434.2935,112 [IMG: BECOME PART OF A DEDICATED TEAM] [H2] BECOME PART OF A DEDICATED TEAM Employees are given optimum conditions for development. We quickly recognise their potential, encourage their creativity and value their dedication to work. More [IMG: Slideshow slide 1] [H2] Movie about Krka 3:00Our core business is development, production, marketing and sales of prescription pharmaceuticals, non-prescription products and animal health products. Operating figures are dynamic. The latest operating figures are published in the latest Annual Report. [H2] Continue browsing [IMG: Multiparty banner 1] [H3] About us We are continually consolidating our position as one of the leading generic pharmaceutical companies in the world.More [H3] Sustainability We can only consider ourselves successful when our success has a positive impact on the environment and the community.More [H3] Health matters Our expert advice is aimed at promoting and raising awareness about the importance of leading a healthy lifestyle.More
4106 chars
SUB-PAGE (https://krka.biz/health-matters/) Health matters | Krka
HomeHealth matters [IMG: Slideshow slide] [H2] Health matters Our expert advice is aimed at promoting and raising awareness about the importance of leading a healthy lifestyle. Our mission is to look after people’s health. We devote as much care to researching and developing a medicine as we do to sharing our knowledge and wealth of experience with renowned experts. Our expert advice is aimed at promoting and raising awareness about the importance of leading a healthy lifestyle. [H3] Valuable health information Diabetes Companion animals Flu and cold Pain Gastrointestinal tract Mental health Cardiovascular system Show all [H2] Product search In our commitment to healthy living we offer a broad range of high-quality prescription pharmaceuticals, non-prescription products and animal health products. Prescription pharmaceuticals Non-prescription products Animal health products [H2] Continue browsing [IMG: Multiparty banner 1] [H3] CLINICALLY PROVEN The quality, safety and efficacy of Krka products have been clinically proven in numerous clinical studies.More [H3] QUALITY We are committed to quality, as it is an essential part of everything we do.More [H3] SCIENCE AND TECHNOLOGY The trust in Krka’s medicines begins in our development laboratories and production facilities.More
1344 chars
SUB-PAGE (https://krka.biz/employment/) Employment | Krka
HomeEmployment [IMG: Slideshow slide] [H2] Employment Creating opportunities for development, learning and networking.1:02 At Krka, knowledge is a value. Krka employees form a dynamic and development-oriented environment in which young people can gain valuable experience and skills. We recognise talented individuals, build our future around them and help them develop into leading experts. JOB OPENINGS [IMG: WHY WORK AT KRKA?] [H2] WHY WORK AT KRKA? Krka’s story is one of expertise and knowledge, quality and innovation, teamwork and strong interpersonal relationships. MORE [IMG: AREAS OF WORK] [H2] AREAS OF WORK At Krka we want to hear from experts in various fields. Key professions that we look for are pharmacists, chemists, physicians, veterinarians, mechanical engineers, electricians, information engineers, economists. MORE [IMG: EMPLOYEES SHARE THEIR STORIES] [H2] EMPLOYEES SHARE THEIR STORIES Krka employees discuss their work and career progress at Krka in their own words. MORE [IMG: Slideshow slide 1] [H2] BECOME A PART OF OUR SUCCESS 1:03Join us and create a career in an international environment. [H2] News [IMG: 2.4 tonnes of donations and 65 litres of blood: numbers that tell the story of Krka’s solidarity] 22. 5. 2026 [H3] 2.4 tonnes of donations and 65 litres of blood: numbers that tell the story of Krka’s solidarity Krka volunteers demonstrated yet again that mutual support, collaboration and willingness to help constitute the core values that bring Krka employees together. For the thirteenth consecutive year, nearly 1,000 volunteers helped spread a culture of care and cooperation through a wide range of activities across Slovenia and 24 other countries. [IMG: Krka once again tops the rankings for reputation and influence] 4. 2. 2026 [H3] Krka once again tops the rankings for reputation and influence Business excellence at Krka reflects a long-term commitment to achieving results that create lasting value for employees, customers, shareholders, and the wider community. [IMG: Krka receives Krka was awarded the TOP investor in learning and development Certificate for the fourth consecutive year] 25. 11. 2025 [H3] Krka receives Krka was awarded the TOP investor in learning and development Certificate for the fourth consecutive year Krka was awarded the TOP Education Management Certificate, reaffirming our commitment to invest in employee education and development. MORE [H2] Continue browsing [IMG: Multiparty banner 1] [H3] SUSTAINABILITY We can only consider ourselves successful when our success has a positive impact on the environment and the community.MORE [H3] ABOUT US We are continually consolidating our position as one of the leading generic pharmaceutical companies in the world.MORE [H3] SCIENCE AND TECHNOLOGY The trust in Krka’s medicines begins in our development laboratories and production facilities.MORE
3236 chars
SUB-PAGE (https://krka.biz/investors/financial-reports/) Financial reports | Krka
HomeInvestorsFinancial reports [IMG: Slideshow slide] [H2] FINANCIAL REPORTS KRKG-. -. — –:–Data delayed 15 minutes.Data source: LJSE.More 2021-10-12,308.0455,111 2021-10-13,184.5625,111.5 2021-10-14,391.449,112.5 2021-10-15,367.7925,112 2021-10-18,500.861,112 2021-10-19,272.9405,111.5 2021-10-20,212.74,112.5 2021-10-21,434.2935,112 Browse through our annual and interim business reports to learn more about Krka’s success. [H4] 2025 ANNUAL REPORT [IMG: Annual report 2025] 20262025202420232022202120202019201820172016201520142013201220112010200920082007Arhiv [H4] Interim Report Unaudited interim report of the Krka Group and the Krka, d. d., Novo mesto for the first quarter of 2026 (.pdf, 1166 kB)Krka Group Q1 2026 Results Presentation (.pdf, 1968 kB)Krka Group Q1 2026 Results Webcast Transcript (.pdf 436 kB) [H4] ANNUAL REPORT Annual report 2025 (pdf., 10516 kB)2025 Supervisory Board Report (.pdf, 394 kB)Annual report 2025 ESEF (.zip, 19526 kB) [H4] Interim Report Unaudited interim report of the Krka Group and the Krka, d. d., Novo mesto for the first quarter of 2025 (.pdf, 1048 kB)Unaudited interim report of the Krka Group and the Krka, d. d., Novo mesto for the first half of 2025 (.pdf, 1083 kB)Unaudited interim report of the Krka Group and the Krka, d. d., Novo mesto January-September 2025 (.pdf, 2940 kB)Krka FY25 Results Presentation (.pdf, 1835 kB) [H4] FINANCIAL STATEMENTS Unaudited consolidated financial statements of the Krka Group and the Krka company for 2025 [H4] ANNUAL REPORT Annual report 2024 (.pdf, 12.211 kB)2024 Supervisory Board Report (.pdf, 240 kB)Annual report 2024 ESEF (.zip, 19.535 kB) [H4] Interim Report Krka Group Business Performance Preliminary Results 2024 Presentation (.pdf, 1376 kB)Krka Group FY 2024 Preliminary Business Performance Results Webcast Transcript (.pdf, 313 kB)Unaudited interim report of the Krka Group and Krka for the period January to September 2024 (.pdf, 1079 kB)Unaudited interim report of the Krka Group and the Krka, d. d., Novo mesto for the first half of 2024 (.pdf, 1083 kB)Unaudited interim report of the Krka Group and the Krka, d. d., Novo mesto for the first quarter of 2024 (.pdf, 1030 kB) [H4] Financial Statements Unaudited consolidated financial statements of the Krka Group and the Krka company for 2024 (.pdf, 568 kB) [H4] ANNUAL REPORT Annual report 2023 (.pdf, 19181 kB)2023 Supervisory Board Report (.pdf, 222 kB)Annual report 2023 ESEF (.zip, 15365 kB) [H4] Interim Report 2023 Preliminary Krka Business Performance Results Webcast Transcript (.pdf, 313 kB)Krka Group FY 2023 Preliminary Results – presentation (.pdf, 1799 kB)Business development 1-9 2023, FY 2023 estimates and 2024 guidance – presentation (.pdf, 1374 kB)Unaudited interim report of the Krka Group and Krka for the period January to September 2023 (.pdf, 1108 kB)H1 2023 Krka Business Performance Results Webcast Transcript (.pdf, 793 kB)Krka Group H1 2023 results presentation (.pdf, 1808 kB)Unaudited interim report of the Krka Group and the Krka, d. d., Novo mesto for the first half of 2023 (.pdf, 1331 kB)Unaudited interim report of the Krka Group and the Krka, d. d., Novo mesto for the first quarter of 2023 (.pdf, 1523 kB) [H4] Financial Statements Unaudited consolidated financial statements of the Krka Group and the Krka company for 2023 (.pdf, 583 kB) [H4] ANNUAL REPORT Annual report 2022 (.pdf, 18023 kB)2022 Supervisory Board Report (.pdf, 388 kB)Annual report 2022 ESEF (.zip, 16426 kB) [H4] Interim Report Unaudited interim report of the Krka group and Krka company for january-september 2022 (.pdf, 1799 kB)The Krka Group and Krka company Semmi-Annual Report for the first half of 2022 (.pdf, 1962 kB)Unaudited interim report of the Krka Group and the Krka, d. d., Novo mesto for the first quarter of 2022 (.pdf, 1849 kB) [H4] Financial Statements Krka Group Business Presentation: FY 2022 Preliminary Results (.pdf, 1785 kB)Unaudited consolidated financial statements of the Krka Group and the Krka company for 2022 (.pdf, 854 kB) [H4] ANNUAL REPORT Annual Report 2021 (.pdf, 10550 kB)2021 Supervisory Board Report (.pdf, 447 kB)Annual report 2021 ESEF (.zip, 16157 kB [H4] INTERIM REPORT Unaudited Interim Report of the Krka Group and Krka, d. d., Novo mesto for the period January to September 2021 (.pdf, 1750 kB)Unaudited Interim Report of the Krka Group and Krka, d. d. for the Half Year Ended 30 June 2021 (.pdf, 1687 kB)Unaudited interim report of the Krka Group and the Krka, d. d., Novo mesto for the first quarter of 2021 (.pdf, 1696 kB) [H4] FINANCIAL STATEMENTS Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka d. d., Novo mesto 2021 (.pdf, 859 kB) [H4] ANNUAL REPORT Annual report 2020 (pdf) (.pdf, 13715 kB)Annual report 2020 (ESEF) (.zip, 9232 kB) [H4] INTERIM REPORT Unaudited interim report of the Krka Group and Krka, d.d., Novo mesto for the period January to September 2020 (.pdf, 1451 kB) Unaudited interim report of the Krka group and Krka, d. d. for the half year ended 30 June 2020 (.pdf, 1805 kB)Unaudited interim report for the Krka group and Krka, d. d. for the first quarter of 2020 (.pdf, 1797 kB) [H4] FINANCIAL STATEMENTS Unaudited consolidated financil statements of the Krka Group and unaudited financial statements of the Krka d. d., Novo mesto 2020 (.pdf, 873 kB) [H4] ANNUAL REPORT Annual report 2019 (digital) (.pdf, 17101 kB)Annual Report 2019 (.pdf, 17101 kB) [H4] INTERIM REPORT Unaudited Interim Report for the Krka Group and the Krka, d. d. for January to September 2019 (.pdf, 1862 kB)Unaudited Interim Report of the Krka Group and Krka, d. d. for the Half Year Ended 30 June 2019 (.pdf, 1975 kB)Unaudited interim report for the Krka group and Krka, d. d. for the first quarter of 2019 (.pdf, 1374 kB) [H4] FINANCIAL STATEMENTS Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka Company for 2019 (.pdf, 959 kB) [H4] ANNUAL REPORT Annual report 2018 (digital) (.pdf, 10296 kB)Annual report 2018 pdf (.pdf, 8409 kB) [H4] INTERIM REPORT Unaudited Interim Report for the Krka Group and Krka, d. d. from January to September 2018 (.pdf, 1734 kB)Krka Group and Krka, d. d. Unaudited Interim Report for the Half Year Ended 30 June 2018 (.pdf, 1787 kB)Unaudited interim report for the Krka group and Krka, d. d. for the first quarter of 2018 (.pdf, 1751 kB) [H4] FINANCIAL STATEMENTS Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka Company for 2018 (.pdf, 686 kB) [H4] ANNUAL REPORT Annual report 2017 (.pdf, 13544 kB) [H4] INTERIM REPORT Unaudited Interim Report for the Krka Group and Company for January to September 2017 (.pdf, 1432 kB)Unaudited Interim Report for the Krka Group and Company for the First Half of 2017 (.pdf, 1659 kB)Unaudited Interim Report for the Krka Group and the Krka Company for the January-March 2017 (.pdf, 1662 kB) [H4] FINANCIAL STATEMENTS Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of Krka for 2017 (.pdf, 1596 kB) [H4] ANNUAL REPORT Annual report 2016 (FlipBook)Annual report 2016 (.pdf, 13953 kB) [H4] INTERIM REPORT Unaudited Interim Report for the Krka Group and the Krka Company for the January-September 2016 (.pdf, 1606 kB)Unaudited Interim Report for the Krka Group and the Krka Company for the First Half of 2016 (.pdf, 1556 kB)Unaudited Interim Report for the Krka Group and the Krka Company for the January-March 2016 (.pdf, 1491 kB) [H4] FINANCIAL STATEMENTS Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka Company for 2016 (.pdf, 906 kB) [H4] Annual Report Annual report 2015 (Online)Annual report 2015 (.pdf, 6671 kB) [H4] Interim Report Unaudited Interim Report for the Krka Group and the Krka Company for January-September 2015 (.pdf, 1204 kB)Unaudited Interim Report for the Krka Group and the Krka Company for the First Half of 2015 (.pdf, 1323 kB)Unaudited Interim Report for the Krka group and the Krka Company for January-March 2015 (.pdf, 1627 kB) [H4] Financial Statements Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka Company for 2015 (.pdf, 1059 kB) [H4] Annual Report Annual report 2014 (Online)Annual report 2014 (Download PDF) (.pdf, 11803 kB) [H4] Interim Report Unaudited Interim Report for the Krka Group and the Krka Company for January-September 2014 (.pdf, 1569 kB)Unaudited interim Report fot the Krka group an the Krka company for the first half of 2014 (.pdf, 1373 kB)Unaudited Interim Report for the Krka group and the Krka Company for January-March 2014(.pdf, 2015 kB) [H4] Financial Statements Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka Company for 2014 (.pdf, 1191 kB) [H4] Annual Report Annual report 2013 (.pdf, 13198 kB) [H4] Interim Report Unaudited Interim Report for the Krka Group and the Krka Company for January-September 2013 (.pdf, 3879 kB)Unaudited Interim Report for the First Half of 2013 (.pdf, 3292 kB)Unaudited Interim Report for the Krka Group and the Krka Company for January-March 2013 (.pdf, 3635 kB) [H4] Financial Statements Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka Company for 2013 (.pdf, 1469 kB) [H4] Annual Report Annual report 2012 (.pdf, 12087 kB) [H4] Interim Report Unaudited Interim Report for the Krka Group and Company for January-September 2012 (.pdf, 2056 kB)Unaudited interim report for the first half of 2012 (.pdf, 1535 kB)Unaudited interim report for the Krka group and the Krka Company for January – March 2012 (.pdf, 1429 kB) [H4] Financial Statements Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka Company for 2012 (.pdf, 364 kB) [H4] Annual Report Annual report 2011 (.pdf, 8950 kB) [H4] Interim Report January – September 2011 interim report (.pdf, 1227 kB)January – June 2011 interim report (.pdf, 622 kB)January – March 2011 interim report (.pdf, 546 kB) [H4] Financial Statements Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka Company for 2011 (.pdf, 569 kB) [H4] Annual Report Annual Report (.pdf, 7989 kB) [H4] Interim Report January – September 2010 interim report (.pdf, 1302 kB)January – June 2010 interim report (.pdf, 1340 kB)January – March 2010 interim report (.pdf, 552 kB) [H4] Financial Statements Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka Company for 2010 (.pdf, 559 kB) [H4] Annual Report Annual report (.pdf, 11780 kB) [H4] Interim Report January – September 2009 interim report (.pdf, 591 kB)January – June 2009 interim report (.pdf, 592 kB)January – March 2009 interim report (.pdf, 460 kB) [H4] Financial Statements Unaudited consolidated financial statements of the Krka Group and unaudited financial statements of the Krka Company for 2009 (.pdf, 205 kB) [H4] Annual Report Annual report (.pdf, 3871 kB) [H4] Interim Report January – September 2008 interim report (.pdf, 445 kB)January – June 2008 interim report (.pdf, 415 kB)January – March 2008 interim report (.pdf, 407 kB) [H4] Financial Statements Unaudited Unconsolidated and Consolidated Financial Statements for 2008 IFRS (.pdf, 174 kB) [H4] Annual Report Annual report (.pdf, 6669 kB)Business report (.pdf, 3444 kB)Financial statements with notes (.pdf, 3274 kB)Annual report summary (.pdf, 752 kB) [H4] Interim Report January – September 2007 interim report (.pdf, 522 kB)January – June 2007 interim report (.pdf, 1193 kB)January – March 2007 interim report (.pdf, 638 kB) [H4] Financial Statements Unaudited Unconsolidated and Consolidated Financial Statements for 2007 IFRS (.pdf, 174 kB) [H3] 2006 [H4] Annual Report Annual report (.pdf, 5955 kB)Business report (.pdf, 2470 kB)Sustainability report (.pdf, 575 kB)Financial statements with notes (.pdf, 2010 kB)Annual report summary (.pdf, 455 kB) [H4] Interim Report January – September 2006 interim report (.pdf, 638 kB)January – June 2006 interim report (.pdf, 1273 kB)January – March 2006 interim report (.pdf, 97 kB) [H4] Financial Statements Unaudited Consolidated Financial Statements for 2006 IFRS (.pdf, 135 kB)Unaudited Unconsolidated Financial Statements for 2006 IFRS (.pdf, 90 kB) [H3] 2005 [H4] Annual Report Business report (.pdf, 9732 kB)Financial statements with notes (.pdf, 4081 kB)Annual report summary (.pdf, 1217 kB) [H4] Interim Report January – September 2005 interim report (.pdf, 99 kB)January – June 2005 interim report (.pdf, 328 kB)January – March 2005 interim report (.pdf, 37 kB) [H4] Financial Statements Non- audited consolidated Financial Statements for 2005 IFRS (.xls, 109 kB)Notes to Non-audited consolidated Financial Statements for 2005 IFRS (.pdf, 159 kB)Audited Unconsolidated Financial Statements for 2005 SAS and IFRS (.xls, 98 kB)Notes to Audited Unconsolidated Financial Statements for 2005 SAS and IFRS (.pdf, 69 kB)Non-audited Unconsolidated Financial Statements for 2005 SAS (.xls, 48 kB)Notes to Non-audited Unconsolidated Financial Statements for 2005 SAS (.pdf, 136 kB) [H3] 2004 [H4] Annual Report Annual Report (.pdf, 1812 kB) [H4] Interim Report January – September 2004 interim report (.pdf, 74 kB)January – June 2004 interim report (.pdf, 651 kB)January – March 2004 interim report (.pdf, 64 kB) [H4] Financial Statements Non-audited Consolidated Financial Statements for 2004 (.xls, 73 kB)Notes to Non-audited Consolidated Financial Statements for 2004 (.pdf, 143 kB)Non-audited Unconsolidated Financial Statements for 2004 (.xls, 212 kB)Notes to Non-audited Unconsolidated Financial Statements for 2004 (.pdf, 84 kB) [H3] 2003 [H4] Annual Report Annual Report (.pdf, 2724 kB) [H4] Interim Report January – June 2003 interim report (.pdf, 147 kB) [H3] 2002 [H4] Annual Report Business Report (.pdf, 2038 kB)Financial Statments with Notes (.pdf, 570 kB)Krka Group Consolidated Annual Report (.pdf, 585 kB) [H4] Interim Report January – June 2002 interim report (.pdf, 141 kB) [H2] News [IMG: Krka Reports First Quarter 2026 Business Results] 14. 5. 2026 [H3] Krka Reports First Quarter 2026 Business Results In the first quarter of 2026, the Krka Group generated revenue of €565.8 million and operating profit of €151.6 million, confirming long-term stable sales growth and sustained operating profitability. EBITDA margin stood at 31%.
15000 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
24Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 10 | 0 |
| /health-matters/ | 4 | 0 |
| /employment/ | 4 | 0 |
| /investors/financial-reports/ | 6 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/health-matters/ — no schema detected (entity gap)
/employment/ — no schema detected (entity gap)
/investors/financial-reports/ — no schema detected (entity gap)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
✓ Less BS than average
Krka has 3.7 points less BS than the average for Medical Devices, Pharma & Biotech.
BS Detector
Medical Devices, Pharma & Biotech BS: Krka (krka.biz)
https://krka.biz
📍 Industry: Medical Devices, Pharma & Biotech
37
BS / 100
Krka is a high-substance corporate entity trapped in a low-substance marketing shell. While its headers are filled with generic wellness fluff, the site’s back-end—specifically its financial archives and news frequency—proves it is a legitimate industrial power. It is a rare case where the BS score is driven by technical omissions (schema) and cliché slogans rather than a lack of actual business substance.
Info Density
Power-words vs. Substance ratio.
7
23% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
2
10% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
10
50% BS
Commodity Fingerprint
Detection of industry clichés/templates.
8
53% BS
Identity & Authority
Expert verifiability & Schema depth.
10
67% BS
Immediately implement Organization and Person schema to bridge the technical authority gap and link to specific executive footprints. Replace the generic H2 ‘LIVING A HEALTHY LIFE’ with a substance-driven H1 that highlights the 70-year tenure and global generic market position. Add direct outbound links to peer-reviewed studies or clinical trial IDs under the ‘CLINICALLY PROVEN’ section to substantiate medical claims. Ensure all mentions of ‘renowned experts’ are accompanied by names and professional credentials to eliminate the expert-footprint gap.
The site perfectly aligns with the Pharmaceutical and Biotech category, emphasizing its role as a generic drug manufacturer. The content supports this through detailed financial reporting, regulatory news, and product category listings for prescription and animal health.
“The score of 37 reflects a company with immense substance that under-utilizes technical trust signals. The primary drivers of the score are the lack of structured data (Identity & Authority) and the use of 'Trust Theatre' review flags without verified external proof links. The remarkably low Semantic Coherence score (representing high consistency) prevents the BS score from reaching the moderate range.”
Verified Analysis Date: May 30, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Krka, captured on May 30, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Krka: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://krka.biz to view the most current version of its content and learn from the source what this company is about and what it offers.